Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Another pharma firm asks court to stop EMA from releasing data

This article was originally published in SRA

Executive Summary

The European Medicines Agency is facing yet another legal challenge in relation to its access to documents policy.

You may also be interested in...



Boost For Transparency As EU Court Backs EMA's Approach To Disclosing Clinical Data

The EU General Court has dismissed three cases by pharmaceutical companies that wanted to prevent the European Medicines Agency from disclosing certain data about their marketed medicines on the grounds that it would harm their commercial interests. Firms now have a clearer idea of the standards they will need to meet to claim their information is commercially confidential.

Greater Civil Society Involvement in Drug Evaluation Will Bring Challenges, Warns EMA Deputy Head

The European Medicines Agency is keen to highlight its landmark policy on proactive publication of clinical data but it’s aware of the challenges involved in this and other transparency initiatives.

Fresh Challenge To EMA's Access To Documents Policy Raises Hopes For Clarity

As the European Medicines Agency's policy on access to documents faces yet another legal challenge, the European Confederation of Pharmaceutical Entrepreneurs is hoping the verdict will demystify what constitutes commercially confidential information in a marketing authorization application.

Latest News
See All
UsernamePublicRestriction

Register

PS118328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel